Emedgene collaborates with Illumina to scale the interpretat

Emedgene collaborates with Illumina to scale the interpretation of genomic data for rare diseases


Emedgene collaborates with Illumina to scale the interpretation of genomic data for rare diseases
USA - English
News provided by
Share this article
Share this article
PALO ALTO, California, Dec. 16, 2020 /PRNewswire/ -- Emedgene, a leading precision medicine intelligence company, announces a non-exclusive partnership with
Illumina Inc. and the integration of automated interpretation into Illumina's TruSight™ Software Suite for rare genetic diseases. Emedgene's Clinical Rare Disease application is one of a portfolio of artificial intelligence (AI)-powered applications for high-throughput genomic interpretation across clinical and research use cases.
Healthcare is in the midst of a leap towards precision medicine. Continued improvements in the cost of next-generation sequencing (NGS) technologies, such as those developed by Illumina, have dramatically accelerated the adoption of genetic testing. Consequently, data generated from genomics doubles every year and is expected to reach 20 exabytes by 2025. The genomic interpretation market transforms data into meaningful insights that improve patient care and impact the many different medical disciplines that incorporate genomics into routine care.

Related Keywords

California , United States , Ryan Taft , Einat Metzer , Emedgene Co , Illumina Trusight Software Suite , Trusight Software Suite , Software Suite , Illumina Inc , Scientific Research At Illumina , Clinical Rare Disease , Scientific Research , கலிஃபோர்னியா , ஒன்றுபட்டது மாநிலங்களில் , ரியான் ட்யாஃப்ட் , மென்பொருள் தொகுப்பு , இல்லுமின இன்க் , அறிவியல் ஆராய்ச்சி இல் இல்லுமின , மருத்துவ ரேர் நோய் , அறிவியல் ஆராய்ச்சி ,

© 2025 Vimarsana